Quick Answer
HERON THERAPEUTICS, INC. /DE/ reported Operating Income Loss of -$2.54 million for the year ending 2025.
- HERON THERAPEUTICS, INC. /DE/ showed an increase of +78.0% in Operating Income Loss from 2024 to 2025.
- This data is from HERON THERAPEUTICS, INC. /DE/'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2011: -$1.32 million | Q2 2011: -$1.54 million | Q3 2011: -$4.09 million | Q1 2012: -$4.77 million | Q2 2012: -$4.38 million | Q3 2012: -$6.05 million | Q1 2013: -$12.75 million | Q2 2013: -$15.21 million | Q3 2013: -$12.66 million | Q1 2014: -$17.32 million | Q2 2014: -$18.79 million | Q3 2014: -$18.95 million | Q1 2015: -$20.36 million | Q2 2015: -$23.01 million | Q3 2015: -$22.49 million | Q1 2016: -$33.31 million | Q2 2016: -$43.07 million | Q3 2016: -$47.73 million | Q1 2017: -$49.30 million | Q2 2017: -$42.06 million | Q3 2017: -$41.31 million | Q1 2018: -$51.99 million | Q2 2018: -$38.85 million | Q3 2018: -$41.78 million | Q4 2018: -$51.31 million | Q1 2019: -$64.70 million | Q2 2019: -$51.78 million | Q3 2019: -$34.85 million | Q4 2019: -$59.36 million | Q1 2020: -$52.73 million | Q2 2020: -$55.75 million | Q3 2020: -$58.38 million | Q4 2020: -$61.30 million | Q1 2021: -$52.11 million | Q2 2021: -$60.47 million | Q3 2021: -$51.71 million | Q1 2022: -$62.92 million | Q2 2022: -$49.50 million | Q3 2022: -$41.88 million | Q1 2023: -$33.06 million | Q2 2023: -$42.40 million | Q3 2023: -$24.93 million | Q1 2024: -$4.80 million | Q2 2024: -$6.45 million | Q3 2024: -$4.46 million | Q1 2025: $3.15 million | Q2 2025: -$1.64 million | Q3 2025: -$4.09 million.
- Over the full 17 years of available data (2009 to 2025), HERON THERAPEUTICS, INC. /DE/'s Operating Income Loss has grown by 75.2%.
- Historical annual values: Fiscal year 2025: -$2.54 million | Fiscal year 2024: -$11.53 million | Fiscal year 2023: -$110.62 million | Fiscal year 2022: -$174.66 million | Fiscal year 2021: -$217.83 million | Fiscal year 2020: -$228.16 million | Fiscal year 2019: -$210.69 million | Fiscal year 2018: -$183.94 million | Fiscal year 2017: -$194.56 million | Fiscal year 2016: -$170.92 million | Fiscal year 2015: -$96.93 million | Fiscal year 2014: -$74.56 million | Fiscal year 2013: -$54.46 million | Fiscal year 2012: -$23.83 million | Fiscal year 2011: -$11.06 million | Fiscal year 2010: -$9.93 million | Fiscal year 2009: -$10.24 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: